ICIs were given as first-line treatment (pembrolizumab, n = 8) because of high PD-L1 NSCLC, in the second-line setting (nivolumab, n = 21) or beyond (nivolumab, n = 6). The gene discussed is CD274; the disease is non-small cell lung carcinoma.